# Tao Fu

> Tao Fu is the founder, CEO, and president of Attovia Therapeutics, a San Carlos, California biotech developing next-generation biologics for immune-mediated diseases using its proprietary ATTOBODY platform. A biologist-turned-business-leader with more than 25 years across pharma, he built his career at McKinsey, Bristol Myers Squibb, Portola Pharmaceuticals, and Zai Lab before starting Attovia, which has raised roughly $255 million to date, including a $90 million Series C in April 2025.

- **Role:** Founder, CEO and President at Attovia Therapeutics
- **Organizations:** Attovia Therapeutics, Frazier Life Sciences, Tr1X Inc., Zai Lab, Portola Pharmaceuticals, Bristol Myers Squibb, Johnson & Johnson, Scios Inc., McKinsey & Company
- **Education:** Undergraduate studies in Biology, Tsinghua University, M.S. in Biology, University of Rochester, MBA, Finance and Marketing, Vanderbilt University, Chartered Financial Analyst (CFA), CFA Institute
- **Known for:** Founded Attovia Therapeutics and built it into a clinical-stage biotech, Raised approximately $255 million in total venture funding across Series A, B and C, Led an oversubscribed $105M Series B in 2024 and a $90M Series C in 2025

## Career timeline

- **Early career** — Consultant at McKinsey & Company
- **Early career** — Business development roles at Scios Inc. and Johnson & Johnson
- **Mid career** — Vice President, Business and Corporate Development at Bristol Myers Squibb
- **Prior role** — EVP and Chief Commercial and Business Officer at Portola Pharmaceuticals
- **Prior role** — President & COO, then Chief Strategy Officer at Zai Lab
- **2022** — Founded Attovia Therapeutics; serves as CEO and President
- **2024** — Attovia raises oversubscribed $105M Series B led by Goldman Sachs Alternatives
- **2025** — Attovia closes $90M Series C led by Deep Track Capital, bringing total raised to ~$255M

## Achievements

- Founded Attovia Therapeutics and built it into a clinical-stage biotech
- Raised approximately $255 million in total venture funding across Series A, B and C
- Led an oversubscribed $105M Series B in 2024 and a $90M Series C in 2025
- Advanced the proprietary ATTOBODY platform toward clinical proof of concept
- Moved lead candidate ATTO-1310 (anti-IL-31) into Phase 1
- Earned a CFA charter alongside science and business graduate degrees
- Held senior leadership roles at Zai Lab, Portola Pharmaceuticals and Bristol Myers Squibb

## Latest updates

- **2025-04** — Attovia announced a $90 million Series C financing led by Deep Track Capital to advance ATTOBODY-based programs through clinical proof of concept.
- **2025-04** — ATTO-1310, a first-in-class anti-IL-31 biologic, in Phase 1 for chronic pruritus; ATTO-3712 anti-IL-13 x IL-31 bispecific slated to begin Phase 1 in H2 2025.

## Links

- Website: https://attovia.com
- LinkedIn: http://www.linkedin.com/in/taofu

---

Profile page: https://yespress.io/tao-fu
Published by YesPress — https://yespress.io
Last updated: 2026-07-24